Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions.
The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery.
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel.
D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs.
Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site.
The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005).
SHIELD II included three key secondary endpoints:
The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005).
The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005).
The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively.
The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II.
The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter.
Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday.
Read Next:Photo by ittawit21 via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Earnings To Watch: NMI Holdings (NMIH) Reports Q2 Results Tomorrow
Mortgage insurance provider NMI Holdings (NASDAQ:NMIH) will be reporting results this Tuesday after the bell. Here's what you need to know. NMI Holdings beat analysts' revenue expectations by 3% last quarter, reporting revenues of $173.2 million, up 10.9% year on year. It was an exceptional quarter for the company, with a solid beat of analysts' net premiums earned estimates and a solid beat of analysts' EPS estimates. Is NMI Holdings a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting NMI Holdings's revenue to grow 7.6% year on year to $174.4 million, slowing from the 13.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.19 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. NMI Holdings has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.2% on average. Looking at NMI Holdings's peers in the property & casualty insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Stewart Information Services delivered year-on-year revenue growth of 20.1%, beating analysts' expectations by 9.2%, and First American Financial reported revenues up 14.2%, topping estimates by 4.9%. Stewart Information Services traded up 10.3% following the results while First American Financial was also up 3.5%. Read our full analysis of Stewart Information Services's results here and First American Financial's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the property & casualty insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. NMI Holdings is down 9.9% during the same time and is heading into earnings with an average analyst price target of $43.71 (compared to the current share price of $38). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
FTAI Aviation Earnings: What To Look For From FTAI
Aircraft leasing company FTAI Aviation (NASDAQ:FTAI) will be announcing earnings results this Tuesday after market close. Here's what you need to know. FTAI Aviation missed analysts' revenue expectations by 2.1% last quarter, reporting revenues of $502.1 million, up 53.7% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EBITDA estimates but a significant miss of analysts' adjusted operating income estimates. Is FTAI Aviation a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting FTAI Aviation's revenue to grow 42.2% year on year to $630.6 million, slowing from the 61.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.39 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. FTAI Aviation has missed Wall Street's revenue estimates three times over the last two years. Looking at FTAI Aviation's peers in the industrial distributors segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Fastenal delivered year-on-year revenue growth of 8.6%, beating analysts' expectations by 0.5%, and Richardson Electronics reported revenues up 9.5%, falling short of estimates by 3.7%. Fastenal traded up 4.2% following the results while Richardson Electronics was also up 10.9%. Read our full analysis of Fastenal's results here and Richardson Electronics's results here. There has been positive sentiment among investors in the industrial distributors segment, with share prices up 6.8% on average over the last month. FTAI Aviation's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $167.26 (compared to the current share price of $115.00). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Business Upturn
38 minutes ago
- Business Upturn
Why are Laurus Labs shares up over 2% today? Explained
By Aditya Bhagchandani Published on July 28, 2025, 09:27 IST Shares of Laurus Labs Ltd surged over 2% to ₹856.25 in early trade on Monday, making it one of the top gainers on the NSE. The sharp upmove comes on the back of a stellar Q1 performance, a major land allotment for expansion, and bullish commentary from top brokerages. Here's what's driving the stock higher: 1. Blockbuster Q1 FY26 Results Laurus Labs posted a net profit of ₹163 crore, up a massive 1,185% YoY from ₹13 crore a year ago. Revenue : ₹1,570 crore (up 31% YoY) : ₹1,570 crore (up 31% YoY) EBITDA : ₹389 crore (up 127% YoY) : ₹389 crore (up 127% YoY) EBITDA Margin: Expanded significantly YoY, reflecting strong operating leverage This marked the company's third consecutive earnings beat, with particularly robust performance in the CDMO (Contract Development and Manufacturing Organization) and ARV (antiretroviral) verticals. 2. Strategic Land Allotment for Laurus Pharma Zone The Andhra Pradesh government allotted 531.77 acres to Laurus in IP Rambilli Phase-II (Anakapalli District) for the development of a Laurus Pharma Zone (LPZ). Planned investment : ₹5,630 crore : ₹5,630 crore Job creation target : 6,350 people : 6,350 people Phased execution over 8 years This land is crucial for Laurus' long-term growth strategy, giving it the physical base to scale up manufacturing capabilities across API, formulations, and novel therapies. 3. Bullish Broker Commentary Motilal Oswal (MOSL) has maintained a 'Buy' rating, raising the target price to ₹970 (from ₹860) Upgraded gross margin guidance to 55–60% (from 50–55%) Strong CDMO visibility and pipeline Raised earnings estimates by 16% for FY26 and 7% for FY27 has maintained a rating, raising the (from ₹860) Antique Stock Broking gave a more balanced view, maintaining a 'Hold' but still raising the target to ₹700 (from ₹520), citing: Limited visibility in CDMO contracts ARV outlook steady but not exceptional Scale-up challenges in Bio CDMO segment gave a more balanced view, but still raising the target to ₹700 (from ₹520), citing: Still, the firm expects ~16% revenue CAGR from FY25 to FY28, and EBITDA margins to rise from 19% to 30% over the same period. Segmental Strength & Capex Plans The CDMO business is growing rapidly , now contributing more meaningfully to revenues , now contributing more meaningfully to revenues The company is also building a new Gene/ADC facility in Hyderabad and a microbial fermentation plant in Vizag and a Plans to invest ₹5,000 crore over the next 5 years, with net debt/EBITDA expected to stay in the 2.2x–2.5x range Market Snapshot: Stock Price : ₹856.25 (up 2.21%) : ₹856.25 (up 2.21%) 52-week range : ₹417.70 – ₹855.00 : ₹417.70 – ₹855.00 Market Cap : ₹460.32 billion : ₹460.32 billion P/E Ratio: 90.53 Laurus Labs' sharp rally today is driven by optimism around its blockbuster Q1 numbers, the government-backed land allotment, and analyst upgrades, all of which point to a long runway for growth. While near-term execution challenges remain, the market appears to be betting on Laurus' transformational expansion strategy and strong positioning in high-value pharma segments. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Please consult your financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
